FDA approved Skinvive by Juvéderm to reduce neck lines and improve neck appearance in adults over the age of 21. The approval marks the first and only hyaluronic acid injectable ...

AMPLIFY-7P randomized 144 post-resection, radiographically NED mKRAS PDAC patients and missed the prespecified DFS primary endpoint in the intent-to-treat analysis. Landmark assessments showed ~14% ...

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...

In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...

Price transparency remains limited due to heterogeneous baselines, missing “before” metrics, and variable sourcing models, ...

Pharmaceutical Executive: How can prohibitive costs for treatments be addressed? Lisa Bollinger: These are oftentimes very ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues the field must evolve beyond the scale, ...

Polaryx’s chief medical officer discusses the regulatory environment for rare, pediatric treatments and how it’s directly impacting clinical trials. Pharmaceutical Executive previously covered FDA’s ...

Partnering and investment efforts focus on executing registrational studies, leveraging patented formulation, differentiated mechanism, and an estimated five million eligible US patients to support ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...